Literature DB >> 24338265

Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.

Vakaramoko Diaby1, Georges Adunlin, Alberto J Montero.   

Abstract

BACKGROUND: Survival modeling techniques are increasingly being used as part of decision modeling for health economic evaluations. As many models are available, it is imperative for interested readers to know about the steps in selecting and using the most suitable ones. The objective of this paper is to propose a tutorial for the application of appropriate survival modeling techniques to estimate transition probabilities, for use in model-based economic evaluations, in the absence of individual patient data (IPD). An illustration of the use of the tutorial is provided based on the final progression-free survival (PFS) analysis of the BOLERO-2 trial in metastatic breast cancer (mBC).
METHODS: An algorithm was adopted from Guyot and colleagues, and was then run in the statistical package R to reconstruct IPD, based on the final PFS analysis of the BOLERO-2 trial. It should be emphasized that the reconstructed IPD represent an approximation of the original data. Afterwards, we fitted parametric models to the reconstructed IPD in the statistical package Stata. Both statistical and graphical tests were conducted to verify the relative and absolute validity of the findings. Finally, the equations for transition probabilities were derived using the general equation for transition probabilities used in model-based economic evaluations, and the parameters were estimated from fitted distributions.
RESULTS: The results of the application of the tutorial suggest that the log-logistic model best fits the reconstructed data from the latest published Kaplan-Meier (KM) curves of the BOLERO-2 trial. Results from the regression analyses were confirmed graphically. An equation for transition probabilities was obtained for each arm of the BOLERO-2 trial.
CONCLUSIONS: In this paper, a tutorial was proposed and used to estimate the transition probabilities for model-based economic evaluation, based on the results of the final PFS analysis of the BOLERO-2 trial in mBC. The results of our study can serve as a basis for any model (Markov) that needs the parameterization of transition probabilities, and only has summary KM plots available.

Entities:  

Mesh:

Year:  2014        PMID: 24338265     DOI: 10.1007/s40273-013-0123-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.

Authors:  Christopher H Jackson; Linda D Sharples; Simon G Thompson
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

Review 3.  Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?

Authors:  Ron Goeree; Vakaramoko Diaby
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-09-26       Impact factor: 3.043

4.  Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.

Authors:  Nicholas R Latimer
Journal:  Med Decis Making       Date:  2013-01-22       Impact factor: 2.583

Review 5.  Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Authors:  J Thompson Coon; M Hoyle; C Green; Z Liu; K Welch; T Moxham; K Stein
Journal:  Health Technol Assess       Date:  2010-01       Impact factor: 4.014

Review 6.  Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Authors:  G Rogers; M Hoyle; J Thompson Coon; T Moxham; Z Liu; M Pitt; K Stein
Journal:  Health Technol Assess       Date:  2012       Impact factor: 4.014

7.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

  7 in total
  39 in total

1.  A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis.

Authors:  Sandjar Djalalov; Jaclyn Beca; Emmanuel M Ewara; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

2.  Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.

Authors:  Kishan K Patel; Amer M Zeidan; Rory M Shallis; Thomas Prebet; Nikolai Podoltsev; Scott F Huntington
Journal:  Blood Adv       Date:  2021-02-23

3.  Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Authors:  Lucy Hui; Gottfried von Keudell; Rong Wang; Amer M Zeidan; Steven D Gore; Xiaomei Ma; Amy J Davidoff; Scott F Huntington
Journal:  Cancer       Date:  2017-06-22       Impact factor: 6.860

4.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544

5.  Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.

Authors:  Anastasiia Kabeshova; Soumaia Ben Hariz; Elyonore Tsakeu; Robert Benamouzig; Robert Launois
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

6.  Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.

Authors:  Vakaramoko Diaby; Georges Adunlin; Simon B Zeichner; Kiran Avancha; Gilberto Lopes; Stefan Gluck; Alberto J Montero
Journal:  Breast Cancer Res Treat       Date:  2014-07-11       Impact factor: 4.872

7.  Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.

Authors:  Vakaramoko Diaby; Georges Adunlin; Askal Ayalew Ali; Rima Tawk
Journal:  Breast Cancer Res Treat       Date:  2014-07-14       Impact factor: 4.872

8.  Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients.

Authors:  Vakaramoko Diaby; Askal A Ali; Georges Adunlin; Christine G Kohn; Alberto J Montero
Journal:  Curr Med Res Opin       Date:  2016-03-02       Impact factor: 2.580

9.  Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China.

Authors:  Ruxu You; Jinyu Liu; David Bin-Chia Wu; XinYu Qian; Boxiang Lyu; Yu Zhang; Nan Luo
Journal:  Cancer Manag Res       Date:  2019-12-05       Impact factor: 3.989

10.  Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.

Authors:  Bin Wu; Xiaohua Gu; Qiang Zhang; Feng Xie
Journal:  Oncologist       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.